Sexually transmitted infections · 2026
Seroprevalence of HSV-1 and HSV-2 in the urban population of Qatar: a population-based study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nasrallah Gheyath K, Issa Farah, Nizamuddin Parveen B, Trad Farah, Qotba Hamda A, Zein Nouran, Younes Nadin, Ismail Ahmed, Ayoub Houssein H, Yassine Hadi M, Chemaitelly Hiam, Abu-Raddad Laith J
Аннотация
OBJECTIVES: Epidemiological data on herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) infections remain limited in the Middle East and North Africa. This study estimated HSV-1 and HSV-2 seroprevalence in the urban population of Qatar and examined associations with demographic characteristics.
METHODS: A retrospective population-based cross-sectional study was conducted using archived serum specimens from a representative SARS-CoV-2 serosurvey undertaken in 2020 with a probability-based stratified sampling design. HSV-1 and HSV-2 IgG antibodies were measured using Mindray CL-900i chemiluminescence immunoassays. Associations were evaluated using logistic regression.
RESULTS: Among 2002 archived specimens with sufficient volume, 2001 were tested for HSV-1 and 1981 for HSV-2. After excluding equivocal results, HSV-1 seroprevalence was 40.4% (789/1955; 95% CI 38.2% to 42.6%) and HSV-2 seroprevalence was 5.0% (99/1974; 95% CI 4.1% to 6.1%). HSV-1 seroprevalence increased from 16.4% (95% CI 12.8% to 20.6%) among those aged 10-19 years to approximately 50% among older age groups. HSV-2 seroprevalence increased steadily from 0.5% (95% CI 0.1% to 1.9%) among those aged 10-19 years to 13.2% (95% CI 7.8% to 20.6%) among those aged ≥60 years. No differences in HSV seroprevalence were observed between sexes. Some nationality differences were observed for HSV-1, with lower seroprevalence among individuals of Indian nationality, while HSV-2 showed small differences across nationalities.
CONCLUSIONS: HSV-1 and HSV-2 seroprevalence in the urban population of Qatar were lower than regional and global estimates. Distinct age-specific patterns were observed, with early-life acquisition of HSV-1 and a gradual increase in HSV-2 seroprevalence across adulthood.
METHODS: A retrospective population-based cross-sectional study was conducted using archived serum specimens from a representative SARS-CoV-2 serosurvey undertaken in 2020 with a probability-based stratified sampling design. HSV-1 and HSV-2 IgG antibodies were measured using Mindray CL-900i chemiluminescence immunoassays. Associations were evaluated using logistic regression.
RESULTS: Among 2002 archived specimens with sufficient volume, 2001 were tested for HSV-1 and 1981 for HSV-2. After excluding equivocal results, HSV-1 seroprevalence was 40.4% (789/1955; 95% CI 38.2% to 42.6%) and HSV-2 seroprevalence was 5.0% (99/1974; 95% CI 4.1% to 6.1%). HSV-1 seroprevalence increased from 16.4% (95% CI 12.8% to 20.6%) among those aged 10-19 years to approximately 50% among older age groups. HSV-2 seroprevalence increased steadily from 0.5% (95% CI 0.1% to 1.9%) among those aged 10-19 years to 13.2% (95% CI 7.8% to 20.6%) among those aged ≥60 years. No differences in HSV seroprevalence were observed between sexes. Some nationality differences were observed for HSV-1, with lower seroprevalence among individuals of Indian nationality, while HSV-2 showed small differences across nationalities.
CONCLUSIONS: HSV-1 and HSV-2 seroprevalence in the urban population of Qatar were lower than regional and global estimates. Distinct age-specific patterns were observed, with early-life acquisition of HSV-1 and a gradual increase in HSV-2 seroprevalence across adulthood.